Zydus Cadila has received the final approval from the USFDA to market Albendazole Tablets USP (US RLD-ALBENZA tablets), 200 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. This medication is used to treat certain tapeworm infections (such as neurocysticercosis and hydatid disease).

The group also received a tentative approval for Pregabalin Capsules (US RLDLyrica) in the strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. Pregabalin is used to help control certain kinds of seizures, painful nerve diseases and fibromyalgia.

The group now has 239 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 6.25, or 1.81%, to trade at Rs 352.40. The total volume of shares traded was 7,475 at the BSE (9.32 a.m., Monday).